Skip to main content

Table 2 Combination scores for eribulin-ifosfamide and eribulin-pazopanib calculated by Synergy finder. Mean of two experiments and SD are included for each algorithm

From: Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

Cell line

Combination

ZIP

HSA

BLISS

LOEWE

HT1080

Eribulin + Ifosfamide

7.27 ± 2.41

10.08 ± 1.94

8.22 ± 2.37

4.39 ± 1.29

SK-UT-1

3.74 ± 0.76

7.07 ± 1.26

4.18 ± 0.84

0.7 ± 2.63

SW872

7.49 ± 4.24

8.75 ± 5.07

7.8 ± 4.32

4.48 ± 4.31

LIPODL221

1.31 ± 1.55

6.07 ± 1.33

2,90 ± 0.34

1.99 ± 0.50

93T449

5,19 ± 0.28

7.74 ± 2.48

6.48 ± 2.38

2.55 ± 1.61

LPS224

6,98 ± 0.04

7.77 ± 0.99

7.81 ± 0.44

4.26 ± 0.34

LPS246

2.27 ± 1.15

5.28 ± 0.17

2.68 ± 1.25

1.69 ± 0.32

SK-UT-1

Eribulin + Pazopanib

4.08 ± 4.34

10.25 ± 0.50

5.17 ± 2.49

5.53 ± 1.31

SW872

8.81 ± 1.92

13.97 ± 0.03

9.19 ± 1.41

8.00 ± 0.03

LIPODL221

3.38 ± 2.29

11.07 ± 1.40

3.37 ± 2.24

7.67 ± 1.98

  1. ZIP Zero Interaction Potency, HSA Highest Single Agent, LOEWE Loewe additivity model, BLISS Bliss model